Recent changes
GovPing tracks 141 sources for this role out of 2,348 total sources on GovPing, covering Guidance, Enforcement, Rule, Notice, and Consultation instruments. There were 722 changes in the last 7 days.
Health Canada issued a Type I recall for nitrous oxide chargers sold by DOODELZ, Gold Whip, and Whip-it! brands without market authorization, while the UK VMD called for a Class II recall of Zoetis's Scabigard Suspension for cutaneous administration. FDA classified Draeger's Atlan A350 anesthesia workstations as a Class I recall due to potential piston ventilator failure, and Morovan recalled approximately 4,000 units of Gel Nail Polish Remover for methylene chloride and chloroform contamination.
Ammonium Chloride Formulations for Viral Defense
The USPTO published patent application US20260097072A1 for ammonium chloride formulations designed to support human natural defense against viral infections. The invention claims compositions and methods using lysosomotropic agents, such as ammonium chloride (NH4Cl), to prevent viral uncoating within lysosomes of infected cells. The patent names Nikolaos Tsirikos-Karapanos and Nikolaos Drakoulis as inventors.
Heterotrophic Skin Bacteria Composition for Treating UV Damage and PLE
The USPTO published patent application US20260097086A1 by inventor Catherine O'Neill for a composition comprising heterotrophic skin bacteria or bacterial extract for modulating cytokine expression in skin cells. The composition is intended for preventing and treating skin damage caused by UV light and for treating polymorphous light eruption (PLE).
Cbfβ-Expressing Vascular Smooth Muscle Cells for Age-Related Disease Treatment
The USPTO published patent application US20260097084A1 by Kyungpook National University Industry-Academic Cooperation Foundation covering a pharmaceutical composition containing Cbfβ-expressing vascular smooth muscle cells or culture fluid for preventing or treating age-related diseases. The invention demonstrates that Cbfβ expression in vascular smooth muscle cells inhibits osteoclast differentiation and prevents vascular calcification, offering potential therapeutic applications for conditions such as osteoporosis and age-related vascular disorders.
Pharmaceutical Composition Containing Neonatal Pig-Derived Mesenchymal Stem Cells for Treating Non-Porcine Animals
USPTO published patent application US20260097081A1 by Fukuoka University for a pharmaceutical composition containing neonatal pig-derived mesenchymal stem cells. The cells produce at least one humoral factor selected from TGF-β1, TGF-β2, VEGF-A, and VEGF-C for therapeutic use in treating cardiovascular conditions, wounds, and decubitus in non-porcine animals. The application was filed on October 10, 2025.
Liposome Composition Comprising Sphingomonas Olei Culture Extract for Skin Delivery
USPTO published patent application US20260096958A1 by six inventors including Won Woo Choi and Byong Jun Choi for a liposome composition encapsulating Sphingomonas olei culture extract for enhanced skin regeneration and transdermal absorption. The application covers cosmetic compositions for topical skin delivery applications, classified under CPC codes A61K 8/14 and A61Q 19/00.
Aerosol Antiperspirant Composition with Basic Aluminum Chloride Salt Formula
USPTO published patent application US20260096955A1 for an aerosol antiperspirant composition containing a basic aluminum chloride salt (formula Al2(OH)3.778Cl2.222 to Al2(OH)5.048Cl0.952), an amino acid, an alkaline earth metal salt, and greater than 1% of an alkali metal salt and/or magnesium chloride. The concentrate includes a particulate active premix, carrier, and fragrance. The application names five inventors and was filed October 3, 2025.
Therapeutic Methods Using Antibody Drug Conjugates (ADCs)
The European Patent Office published patent application EP3801635A2 by Regeneron Pharmaceuticals covering therapeutic methods using Antibody Drug Conjugates (ADCs) for cancer (A61P 35/00) and immune disorders (A61P 37/00). The patent designates all EU member states including Germany, France, UK, Italy, Spain, and others. This IP protection covers ADC methods linked to A61K 47/68 and C07K 16/28 classifications.
Chimeric Antigen Receptor Comprising Third Signal Receptor for Cancer Therapy
The European Patent Office published patent application EP3812401A1 for Shanghai Longyao Biotechnology Inc., covering a chimeric antigen receptor (CAR) comprising a third signal receptor for cancer therapy. The application claims priority to the A61P 35/00 classification for antineoplastic agents. The patent is published with IPC classifications C07K 19/00 and A61K 48/00, with designated states covering all EU member states plus other European countries.
Nitroimidazole patent EP3810137A1 filed 1st Apr, IRP Health
Nitroimidazole patent EP3810137A1 filed 1st Apr, IRP Health
Novel Topical Intradermal Formulation and Uses Thereof
The European Patent Office has published patent application EP3843732A1 by Arctic Therapeutics hf. for a novel topical intradermal formulation with pharmaceutical applications. The patent covers dermatological treatments including psoriasis (A61P 17/06) and skin conditions (A61P 17/10), with protection extending to 31 designated European states including Germany, France, and the UK. Inventors include Hakonarson, Kao, Kisak, Newsam, and Kushwaha.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
737 changes in last 7 days
Latest high priority updates
142 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.